Reports Q4 revenue $201.81M, consensus $192.14M. “We fired on all cylinders throughout 2024, delivering remarkable revenue growth and upgrading our products to our smart liquid biopsy platform,” said Helmy Eltoukhy, co-founder and co-CEO, on Thursday. “Last month, we were pleased to receive Medicare reimbursement for Guardant Reveal in the CRC surveillance setting, which was an important milestone for our MRD business. We are entering 2025 with a strong oncology product portfolio and anticipate volume acceleration across all our products this year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $56 from $42 at TD Cowen
- Guardant Health price target raised to $59 from $39 at Raymond James
- Guardant Health price target raised to $60 from $55 at BTIG
- Guardant Health price target raised to $56 from $49 at Guggenheim
- Guardant Health’s Promising Growth Prospects: Buy Rating Backed by Strong Revenue Guidance and Optimistic Projections